Rekha Kouri, DPM
Foot & Ankle Surgery · Plano, TXNPI 1659995876
Payments from drug & device makers
Across 114 payments — averaging $162.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elite Orthopedics, LLC$15K
- Arthrex$1K
- Paratek Pharmaceuticals, Inc.$376
- Averitas Pharma Inc.$354
- Integra Lifesciences Corporation$283
- Stryker$236
- plus $980 from 19 others
What the payments were for
- Travel & lodging$1,6939%
- Food & beverage$3,22117%
- Education$13,65874%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elite Orthopedics, LLC | 33 | $15,308 |
| Arthrex | 14 | $1,035 |
| Paratek Pharmaceuticals, Inc. | 17 | $376 |
| Averitas Pharma Inc. | 11 | $354 |
| Integra Lifesciences Corporation | 4 | $283 |
| Stryker | 3 | $236 |
| Convatec Inc. | 2 | $163 |
| Smith+Nephew | 4 | $123 |
| Treace Medical Concepts, Inc. | 2 | $122 |
| Johnson & Johnson | 2 | $81 |
| AbbVie | 2 | $56 |
| Medtronic | 2 | $56 |
| DJO, LLC | 1 | $53 |
| ETS Wound Care LLC | 2 | $45 |
| Melinta Therapeutics, LLC | 2 | $39 |
| Amgen | 2 | $34 |
| Organogenesis Inc. | 2 | $33 |
| Medline Industries LP | 1 | $29 |
| Zimmer Biomet | 1 | $28 |
| Bioventus LLC | 1 | $25 |
| Reapplix Inc. | 1 | $21 |
| Vertex | 1 | $20 |
| Kerecis Limited | 2 | $20 |
| KCI USA, Inc. | 1 | $17 |
| Hartmann USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,573 in reported general payments places this provider in the 80th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 11 | $303 |
| Mupirocin | 38 | $286 |
| Methylprednisolone | 40 | $270 |
| Ciclopirox | 12 | $235 |
| Terbinafine Hcl | 29 | $217 |
| Ketoconazole | 14 | $208 |
| Doxycycline Hyclate | 22 | $156 |
| Cephalexin | 16 | $97 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $48 |
| Gabapentin | 13 | $42 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Plano
- Christopher SakowskiPlano$107K
- Richard PollakSan Antonio$6.1M
- Joseph CaporussoMcAllen$6M
- Mark DaltonAustin$4.1M
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Chad HowzeSan Antonio$2.4M
- Graham HamiltonEdinburg$2.1M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$972K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.